Background
Cardiovascular Magnetic Resonance (CMR) by late gadolinium enhancement (LGE) allows to detect myocardial fibrosis. Myocardial fibrosis was shown to be a relative common finding in large cohort of Italian thalassemia major (TM) patients mainly related to HCV infection, but specific studies involving only pediatric patients are not available. Our aim was to investigate the prevalence and clinical-instrumental correlates of myocardial fibrosis in pediatric TM patients.
Methods
We studied retrospectively 76 pediatric patients with TM (44 boys, 4.2 -17.9 years old, mean age 13.6 ± 3.4 years) enrolled in the MIOT (Myocardial Iron Overload in Thalassemia) Network. All patients were well transfused and chelated since the early childhood.LGE images were acquired to detect myocardial fibrosis. Myocardial iron overload (MIO) was measured by T2* multislice multiecho technique. Biventricular function parameters were quantitatively evaluated by cine images.
Results
Myocardial fibrosis was detected in 12 (15.8%) patients. In all patients the location of the fibrosis was epi-mesocardial, with no ischemic pattern. The youngest patient showing myocardial fibrosis had 13 years of age. Table 1 shows the comparison between patients with and without myocardial fibrosis. A significant higher MIO was detected in patients with myocardial fibrosis. The left atrial area, all the left 1 CMR Unit, Fondazione G.Monasterio CNR-Regione Toscana and Institute of Clinical Physiology, Pisa, Italy Full list of author information is available at the end of the article ventricular (LV) indexed volumes, the LV mass index and the bi-ventricular stroke volume indexes were significantly higher in the fibrosis group than in the no-fibrosis group.
Conclusions
In pediatric TM patients myocardial fibrosis is not a rare finding to keep in mind in the cardiological management. When appropriate treatment has been administered since early childhood, CMR LGE can be postponed until 13 years of age. By the natural history of this large cohort of pediatric patients where HCV infection has been appropriately prevented, myocardial fibrosis seem to be associated with MIO and high cardiac output.
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